カテゴリ： GlobalData, 企業調査, 香港

Lee’s Pharmaceutical Holdings Ltd (950)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Lee's Pharmaceutical Holdings Ltd (950) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8030
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：香港
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Lee’s Pharmaceutical Holdings Ltd (Lee’s Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology, ophthalmology, dermatology, and gynecology. Its products are used for therapeutic indications that include cornea ulcer, reduction of bleeding, viral-infected venereal diseases, and other cardiovascular diseases. Lee’s Pharmaceutical offers pipeline products for cardiovascular, oncology related diseases; ophthalmology, dermatology, and ophthalmology are in different preclinical stages. The company works in partnership with other organizations for the development, and distribution rights for products across the US, Japan and Europe. It operates through its manufacturing facility located at Hefei City, China. Lee’s Pharmaceutical is headquartered in Hong Kong.

Lee’s Pharmaceutical Holdings Ltd (950) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lee’s Pharmaceutical Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lee’s Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Tragara Pharma Raises USD13 Million in Series C Financing 16
Partnerships 18
Lee’s Pharma Enters into Agreement with Shenogen Pharma 18
Lee’s Pharma Enters into Agreement with Beijing Shenogen Pharma 19
ScinoPharm Enters into Agreement with CVie Therapeutics 20
INO Therapeutics Enters into Agreement with Lee’s Pharma for Inomax 21
ScinoPharm Enters Into Co-Development Agreement With Lee’s Pharma For Fondaparinux Sodium 22
ScinoPharm Announces Co-Development Agreement With Lee’s Pharma For Travoprost And Bimatoprost 23
Licensing Agreements 24
Lee’s Pharma Enters into Licensing Agreement with Alexza Pharma 24
Lee’s Pharma Enters into Licensing Agreement with GC Pharma 25
Lee’s Pharma Enters into Licensing Agreement with Noden Pharma 26
Lee’s Pharma Enters into Licensing Agreement with Windtree Therapeutics 27
Lee’s Pharma Enters into Licensing Agreement with Solasia Pharma 29
Lee’s Pharma Enters into Licensing Agreement with TOT Biopharm 30
Lee’s Pharma Enters into Licensing Agreement with Kato Pharma 31
Laboratorios SALVAT Enters into Licensing Agreement with Lee’s Pharma 32
Lee’s Pharma Enters into Licensing Agreement with Solasia Pharma for Sancuso 33
Lee’s Pharma Enters into Licensing Agreement with Tragara Pharma 34
China Cardiovascular Focus Enters into Licensing Agreement with Armetheon 35
Lee’s Pharma Enters into Licensing Agreement with BioQuiddity 36
Sorrento Therapeutics Enters into Licensing Agreement with Lee’s Pharma for Anti-PD-L1 Antibody 37
Abiogen Pharma Enters into Licensing Agreement with Lee’s Pharma for Thorens Cholecalciferol 38
Abiogen Pharma Enters into Licensing Agreement with Lee’s Pharma for Attila 39
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor 40
RegeneRx Biopharma Enters into Licensing Agreement with Lee’s Pharma for RGN-259, RGN-352 and RGN-137 41
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 43
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 45
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 47
PLx Pharma Enters into Licensing Agreement with Lee’s Pharma for Cardiovascular Product 48
Dilafor Enters Into Licensing Agreement With Lee’s Pharma 49
Lee’s Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 50
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 51
Equity Offering 52
Windtree Therapeutics Raises USD2.6 Million in Private Placement of Shares 52
CVie Therapeutics Raises USD10 Million in Private Placement of Shares 54
Asset Transactions 55
Lee’s Pharma to Sell Products to China Oncology Focus for USD13.6 Million 55
Zhaoke Pharma to Sell Products to China Oncology Focus for USD0.9 Million 56
Acquisition 57
Lee’s Pharmaceutical Acquires 65% Stake in China Oncology Focus 57
Lee’s Pharmaceutical Holdings Ltd – Key Competitors 58
Lee’s Pharmaceutical Holdings Ltd – Key Employees 59
Lee’s Pharmaceutical Holdings Ltd – Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Affiliate 60
Recent Developments 62
Financial Announcements 62
Aug 30, 2018: Lee’s Pharmaceutical Holdings: Interim results for the six months ended 30 June 2018 62
May 24, 2018: Lee’s Pharmaceutical Holdings: First Quarterly Results For The Three Months Ended 31 March 2018 65
Mar 22, 2018: Lee’s Pharmaceutical Holdings:Announcement Of Annual Results For The Year Ended 31 December 2017 67
Aug 24, 2017: Lee’s Pharmaceutical Holdings: Interim Results For The Six Months Ended 30 June 2017 72
Corporate Communications 74
Dec 29, 2017: Lee’s Pharmaceutical Holdings: Resignation and Appointment of Non-Executive Director 74
Product News 76
03/09/2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial 76
Other Significant Developments 77
May 28, 2018: Lee’s Pharmaceutical: Change Of Address Of Head Office And Principal Place Of Business In Hong Kong 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lee's Pharmaceutical Holdings Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Lee's Pharmaceutical Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Tragara Pharma Raises USD13 Million in Series C Financing 16
Lee's Pharma Enters into Agreement with Shenogen Pharma 18
Lee’s Pharma Enters into Agreement with Beijing Shenogen Pharma 19
ScinoPharm Enters into Agreement with CVie Therapeutics 20
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 21
ScinoPharm Enters Into Co-Development Agreement With Lee’s Pharma For Fondaparinux Sodium 22
ScinoPharm Announces Co-Development Agreement With Lee’s Pharma For Travoprost And Bimatoprost 23
Lee’s Pharma Enters into Licensing Agreement with Alexza Pharma 24
Lee's Pharma Enters into Licensing Agreement with GC Pharma 25
Lee's Pharma Enters into Licensing Agreement with Noden Pharma 26
Lee’s Pharma Enters into Licensing Agreement with Windtree Therapeutics 27
Lee’s Pharma Enters into Licensing Agreement with Solasia Pharma 29
Lee's Pharma Enters into Licensing Agreement with TOT Biopharm 30
Lee's Pharma Enters into Licensing Agreement with Kato Pharma 31
Laboratorios SALVAT Enters into Licensing Agreement with Lee’s Pharma 32
Lee's Pharma Enters into Licensing Agreement with Solasia Pharma for Sancuso 33
Lee's Pharma Enters into Licensing Agreement with Tragara Pharma 34
China Cardiovascular Focus Enters into Licensing Agreement with Armetheon 35
Lee’s Pharma Enters into Licensing Agreement with BioQuiddity 36
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 37
Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Thorens Cholecalciferol 38
Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Attila 39
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor 40
RegeneRx Biopharma Enters into Licensing Agreement with Lee's Pharma for RGN-259, RGN-352 and RGN-137 41
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 43
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 45
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 47
PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 48
Dilafor Enters Into Licensing Agreement With Lee’s Pharma 49
Lee's Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 50
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 51
Windtree Therapeutics Raises USD2.6 Million in Private Placement of Shares 52
CVie Therapeutics Raises USD10 Million in Private Placement of Shares 54
Lee's Pharma to Sell Products to China Oncology Focus for USD13.6 Million 55
Zhaoke Pharma to Sell Products to China Oncology Focus for USD0.9 Million 56
Lee’s Pharmaceutical Acquires 65% Stake in China Oncology Focus 57
Lee's Pharmaceutical Holdings Ltd, Key Competitors 58
Lee's Pharmaceutical Holdings Ltd, Key Employees 59
Lee's Pharmaceutical Holdings Ltd, Subsidiaries 60
Lee's Pharmaceutical Holdings Ltd, Affiliate 60

List of Figures
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lee's Pharmaceutical Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Lee’s Pharmaceutical Holdings Ltd (950)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Snyder’s-Lance Inc：企業の戦略的SWOT分析
    Snyder's-Lance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • SRCTec, Inc.：企業の戦略・SWOT・財務情報
    SRCTec, Inc. - Strategy, SWOT and Corporate Finance Report Summary SRCTec, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sumitomo Heavy Industries Ltd (6302)：電力：M&Aディール及び事業提携情報
    Summary Sumitomo Heavy Industries Ltd (Sumitomo) is a manufacturer of industrial machinery. The company offers a range of products, which include pumps, steam turbines, energy plants, iron and steel manufacturing machinery, cryogenics, environmental systems. It also provides water treatment plants, …
  • EnviTec Biogas AG (ETG)：企業の財務・戦略的SWOT分析
    EnviTec Biogas AG (ETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Luxottica Group S.p.A.：企業の戦略・SWOT・財務情報
    Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ConvaTec Group Plc (CTEC)：医療機器：M&Aディール及び事業提携情報
    Summary ConvaTec Group Plc (ConvaTec) is a medical products and technologies company that specializes in advanced wound care, ostomy care, continence and critical care, and infusion devices. Its major products include wound dressings, skin care products, disposable infusion sets, urological catheter …
  • Bank of Taiwan：企業の戦略・SWOT・財務分析
    Bank of Taiwan - Strategy, SWOT and Corporate Finance Report Summary Bank of Taiwan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • TESARO Inc (TSRO)：医療機器：M&Aディール及び事業提携情報
    Summary TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The co …
  • Occidental Petroleum Corporation (OXY)-石油・ガス分野：企業M&A・提携分析
    Summary Occidental Petroleum Corporation (Occidental) is an oil and gas exploration and production company with integrated assets. The company is active in upstream exploration and production; midstream and marketing; and chemicals business. The oil and gas business explores for, develops and produc …
  • Orchids Paper Products Co (TIS)：企業の財務・戦略的SWOT分析
    Orchids Paper Products Co (TIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • The Lubrizol Corp：企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Sany Heavy Industry Co Ltd (600031)：企業の財務・戦略的SWOT分析
    Sany Heavy Industry Co Ltd (600031) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ali Baba：企業の戦略・SWOT・財務情報
    Ali Baba - Strategy, SWOT and Corporate Finance Report Summary Ali Baba - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • China Suntien Green Energy Co Ltd (956)：企業の財務・戦略的SWOT分析
    China Suntien Green Energy Co Ltd (956) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Hess Corporation：企業の戦略・SWOT・財務分析
    Hess Corporation - Strategy, SWOT and Corporate Finance Report Summary Hess Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Avanti Feeds Ltd (AVANTIFEED)：企業の財務・戦略的SWOT分析
    Avanti Feeds Ltd (AVANTIFEED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Linamar Corporation (LNR)：企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Terramin Australia Ltd：企業の戦略・SWOT・財務分析
    Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Enthera Srl：製薬・医療：M&Aディール及び事業提携情報
    Summary Enthera Srl (Enthera), a subsidiary of BiovelocITA Srl, is a biotechnology company, which strives to discover novel medicines for the treatment of diabetes and related gastrointestinal disorders. Gastrointestinal symptoms such as diarrhea and abdominal pain among diabetics are referred to as …
  • Camurus AB (CAMX)：企業の財務・戦略的SWOT分析
    Summary Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s technology includes smart and versatile drug delivery, injection depot, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆